Search

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,183 questions · 1,283 findings · 30 reviews · Oral medicine and oral cancer

No studies found 164 · 12.8%GRADE not reported 802 · 62.5%Very low 209 · 16.3%Low 71 · 5.5%Moderate 36 · 2.8%High 1 · 0.1%

Any antifungal intervention for the treatment of oral candidiasis vs Placebo, no treatment, or another active antifungal intervention

Relief of dysphagia · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

The review found no eligible studies for this question.

1 finding from 1 review

GM-CSF vs Antimycotic mouthrinse

Time to heal mucositis (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Granulocyte macrophage-colony stimulating factor (GM-CSF) led to lower time to heal mucositis (days) compared with antimycotic mouthrinse; GRADE not reported.

1 finding from 1 review

Partially absorbed antifungal drug (e.g., clotrimazole, miconazole) vs Absorbed antifungal drug (e.g., fluconazole, ketoconazole, itraconazole)

Outcome not reported · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

The review found no eligible studies for this question.

1 finding from 1 review

Radiotherapy (morning) vs Afternoon radiotherapy

Locoregional control · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…

Morning radiotherapy showed no clear difference in locoregional control compared with afternoon radiotherapy; GRADE not reported.

1 finding from 1 review

Therapist support (visits) vs control (e.g. usual activities)

Daily mean opiate intake per hour · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Therapist support (visits) showed no clear difference in daily mean opiate intake per hour compared with control (treatment as usual); GRADE not reported.

1 finding from 1 review

Morphine via patient-controlled analgesia (PCA) vs Morphine via continuous infusion (CI)

Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Morphine via patient-controlled analgesia (PCA) showed no clear difference in average pain scores (0-100 VAS) compared with morphine via continuous infusion (CI); GRADE not reported.

1 finding from 1 review

Morphine via pharmacokinetically based PCA (PKPCA) vs Morphine via patient-controlled analgesia (PCA)

Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Morphine via pharmacokinetically based PCA (PKPCA) led to lower average pain scores (0-100 VAS) compared with morphine via patient-controlled analgesia (PCA); GRADE not reported.

1 finding from 1 review

Any antifungal intervention for the treatment of oral candidiasis vs Placebo, no treatment, or another active antifungal intervention

Relief of pain · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

The review found no eligible studies for this question.

1 finding from 1 review

Benzydamine hydrochloride mouthwash vs placebo

Improvement in mucositis · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Benzydamine hydrochloride mouthwash showed no clear difference in improvement in mucositis compared with placebo; GRADE not reported.

1 finding from 1 review

Morphine via patient-controlled analgesia (PCA) vs Morphine via continuous infusion (CI)

Duration of pain control therapy (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Morphine via patient-controlled analgesia (PCA) led to lower duration of pain control therapy (days) compared with morphine via continuous infusion (CI); GRADE not reported.

1 finding from 1 review

Lower total dose radiotherapy (67.2 Gy over 5.6 weeks) vs conventional dose RT

Total mortality · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…

Lower total dose radiotherapy (67.2 Gy over 5.6 weeks) showed no clear difference in total mortality compared with conventional/standard total dose radiotherapy (72 Gy); GRADE not reported.

1 finding from 1 review

Fluconazole (absorbed from GI tract) vs Ketoconazole (absorbed from GI tract)

Clinical: eradication of oral candidiasis · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

Fluconazole (absorbed from GI tract) showed no clear difference in clinical: eradication of oral candidiasis compared with ketoconazole (absorbed from GI tract); GRADE not reported.

1 finding from 1 review

Any antifungal intervention for the treatment of oral candidiasis vs Placebo, no treatment, or another active antifungal intervention

Patient quality of life · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

The review found no eligible studies for this question.

1 finding from 1 review